We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+57.73%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.27B
AUM Growth
+$886M
Cap. Flow
+$626M
Cap. Flow %
27.61%
Top 10 Hldgs %
43.12%
Holding
273
New
99
Increased
46
Reduced
48
Closed
43

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$15.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.4M
3
PRTA icon
Prothena Corp
PRTA
+$14M
4
BMY icon
Bristol-Myers Squibb
BMY
+$11.6M
5
PCVX icon
Vaxcyte
PCVX
+$9.67M

Top Sells

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$15.3M
2
ETNB
89bio
ETNB
+$7.86M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.57M
4
RPTX
Repare Therapeutics
RPTX
+$5.86M
5
ATRA icon
Atara Biotherapeutics
ATRA
+$5.53M

Sector Composition

Rank Sector Weight
1 Healthcare 23.89%
2 Industrials 0.04%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
51
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$10.2M 0.45%
+119,100
New +$10.1M
GOSS icon
52
Gossamer Bio
GOSS
$82.9M
$10.1M 0.45%
1,048,383
+465,889
+80% +$4.59M
XBI icon
53
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$9.86M 0.43%
+70,000
New +$8.97M
BDTX icon
54
Black Diamond Therapeutics
BDTX
$96.8M
$9.42M 0.42%
293,941
-65,000
-18% -$2.14M
MRUS
55
DELISTED
Merus
MRUS
$9.41M 0.41%
+536,921
New +$7.93M
KYNB
56
PUT
Kyntra Bio
KYNB
$27.2M
$9.34M 0.41%
10,076
+2,000
+25% +$2.1M
KURA icon
57
CALL
Kura Oncology
KURA
$800M
$9.31M 0.41%
285,000
+65,600
+30% +$2.31M
LYRA
58
DELISTED
LYRA THERAPEUTICS INC
LYRA
$9.29M 0.41%
16,307
+8,548
+110% +$4.82M
CMPS
59
CALL
Compass Pathways
CMPS
$1.53B
$8.95M 0.39%
+187,800
New +$8.01M
ITCI
60
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$8.93M 0.39%
280,989
+40,000
+17% +$1.05M
BHVN
61
PUT
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$8.92M 0.39%
+104,100
New +$8.82M
VTGN icon
62
VistaGen Therapeutics
VTGN
$9.89M
$8.7M 0.38%
+149,532
New +$3.82M
GBT
63
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$8.66M 0.38%
+200,000
New +$9.86M
ARVN icon
64
PUT
Arvinas
ARVN
$518M
$8.49M 0.37%
+100,000
New +$3.45M
ASND icon
65
CALL
Ascendis Pharma A/S
ASND
$16B
$8.46M 0.37%
50,700
-94,300
-65% -$15.6M
MCRB icon
66
CALL
Seres Therapeutics
MCRB
$46.8M
$8.36M 0.37%
17,055
-21,065
-55% -$12.3M
ALLK
67
CALL
DELISTED
Allakos
ALLK
$8.22M 0.36%
+58,700
New +$6.11M
DCPH
68
CALL
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$7.99M 0.35%
140,000
– –
SCPH
69
DELISTED
scPharmaceuticals
SCPH
$7.76M 0.34%
1,466,147
-15,000
-1% -$117K
CRDF icon
70
PUT
Cardiff Oncology
CRDF
$66.5M
$7.52M 0.33%
+417,900
New +$7.34M
ARDX icon
71
Ardelyx
ARDX
$1.22B
$7.48M 0.33%
1,155,436
-375,000
-25% -$2.23M
PCVX icon
72
Vaxcyte
PCVX
$7.81B
$7.34M 0.32%
276,110
+260,000
+1,614% +$9.67M
VIR icon
73
PUT
Vir Biotechnology
VIR
$1.46B
$7.18M 0.32%
+268,000
New +$8.71M
NBP
74
NovaBridge Biosciences American Depositary Shares
NBP
$185M
$7.07M 0.31%
150,000
– –
SAGE
75
CALL
DELISTED
Sage Therapeutics
SAGE
$7.07M 0.31%
81,700
+2,400
+3% +$177K
1 2
3
4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Ikarian Capital held 273 positions worth $2.27B, up 64% from $1.38B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Ikarian Capital deployed $626M of net new capital in Q4 2020, opening 99 new positions and adding to 46 existing holdings. Its largest new stake was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 25% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Ocular Therapeutix, an estimated $15.3M trimmed.

  • Ikarian Capital's largest Q4 2020 buy was Morphic Holding, Inc. Common Stock: 516,763 shares worth $17.3M.
  • Ikarian Capital added most to Bristol-Myers Squibb in Q4 2020, an estimated $11.6M increase.
  • Ikarian Capital's biggest Q4 2020 reduction was Ocular Therapeutix, cutting an estimated $15.3M.
  • Ikarian Capital fully exited Repare Therapeutics in Q4 2020, selling an estimated $5.86M.
  • Ikarian Capital's ten largest holdings make up 43% of its $2.27B portfolio in Q4 2020.
  • Ikarian Capital opened 99 new positions and closed 43 in Q4 2020.
  • Ikarian Capital's portfolio value rose 64% quarter-over-quarter to $2.27B.

Based on Ikarian Capital's 13F filing for Q4 2020, filed 12 Feb 2021.